Former Legend CEO lands at K2—Chutes & Ladders
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. | Just weeks after Legend Biotech announced the departure of its CEO, Ying Huang, K2 Therapeutics has announced that Wang will now lead the startup, which was founded in 2024 with a $50 million seed round from MPM BioImpact.